<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523885</url>
  </required_header>
  <id_info>
    <org_study_id>HLM_JDR3</org_study_id>
    <nct_id>NCT02523885</nct_id>
  </id_info>
  <brief_title>Use of Non Steroidal Antiinflammatory Drugs in Patients With Community Acquired Pneumonia</brief_title>
  <acronym>ALPAJ</acronym>
  <official_title>Descriptive Analysis of Non Steroidal Antiinflammatory Drugs Use in Patients Diagnosed With Community Acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Louis Mourier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Louis Mourier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate exposure to nonsteroidal antiinflammatory drugs (NSAIDs) during outpatient&#xD;
      management at the early stage of community-acquired pneumonia (CAP) requiring hospital&#xD;
      consultation. Non-interventional observational study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent data suggests that such exposure to NSAIDs is associated with delay in CAP diagnosis&#xD;
      and antibiotic prescription that influence CAP presention and outcome. The investigators'&#xD;
      working hypothesis is that NSAIDs use may mask initial symptoms and delay antimicrobial&#xD;
      therapy, thus predisposing to worse outcomes. All patients presenting at one of the three&#xD;
      following locations (emergency department, ICU or pneumology ward) with a suspicion of&#xD;
      community-acquired pneumonia will be screened for eligibility. Exposure or not to NSAIDs will&#xD;
      be investigated. Clinical, biological and radioloigcal features and outcome of CAP will be&#xD;
      compared with respect to NSAIDs exposure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>binary composite primary endpoint</measure>
    <time_frame>28 days</time_frame>
    <description>presence or absence of one or more of the following : occurrence of at least one pneumonia-related complication; need for ICU admission; prolonged length of hospital stay.&#xD;
pneumonia-related complications include: worsening of hypoxemia; need for mechanical ventilation; occurrence or increase of pleural effusion; empyema; occurrence of septic shock;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pneumonia severity index</measure>
    <time_frame>2 days</time_frame>
    <description>the pneumonia severity index calculated at inclusion will be compared in exposed and non-exposed to NSAID patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CURB score at inclusion</measure>
    <time_frame>2 days</time_frame>
    <description>the CURB score (confusion, blood urea nitrogen, respiratory rate and systolic blood pressure) at inclusion will be compared in exposed and non-exposed to NSAID patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of antimicrobial therapy</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurence of a nosocomial infection</measure>
    <time_frame>28 days</time_frame>
    <description>occurrence of nosocomial infections (including nosocomial pneumonia, catheter-related blood stream infection, and urinary tract nosocomial infection) will be compared in exposed and non-exposed to NSAID patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>chest pain</measure>
    <time_frame>2 days</time_frame>
    <description>presence or absence of chest pain at inclusion will compared between exposed and non-exposed to NSAID patients</description>
  </other_outcome>
  <enrollment type="Actual">181</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        all adult patient presenting either to the emergency department or admitted directly to the&#xD;
        ICU or the pneumology ward with a suspicion of CAP will be screened&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: at least two among the following signs&#xD;
&#xD;
          -  temperature &gt; 37.8 °C&#xD;
&#xD;
          -  respiratory rate &gt; 25/min&#xD;
&#xD;
          -  heat rate &gt; 100/min&#xD;
&#xD;
          -  cough&#xD;
&#xD;
          -  expectoration&#xD;
&#xD;
          -  chest pain&#xD;
&#xD;
          -  crackles upon lung auscultation&#xD;
&#xD;
        and new infiltrate on the chest x-ray&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ongoing pregnancy&#xD;
&#xD;
          -  sickle cell disease&#xD;
&#xD;
          -  tracheostomy&#xD;
&#xD;
          -  long term oxygen therapy&#xD;
&#xD;
          -  cystic fibrosis or bronchiectasis&#xD;
&#xD;
          -  neutropenia (&lt; 500 cells/mm3)&#xD;
&#xD;
          -  ongoing solid or hematologic cancer or anticancerous chemotherapy&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  liver cirrhosis&#xD;
&#xD;
          -  long term corticosteroid treatment (20mg per day equivalent prednisone for more than&#xD;
             15 days)&#xD;
&#xD;
          -  preexisting treatment with NSAIDs for more than 15 days&#xD;
&#xD;
          -  hospital admission for more than 48hours&#xD;
&#xD;
          -  aspiration pneumonia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Damien RICARD, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Asssistance Pulique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muriel FARTOUKH, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan MESSIKA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillaume Voiriot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Hajage, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis Mourier Hospital</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Max Fourestier</name>
      <address>
        <city>Nanterre</city>
        <zip>92000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenon Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Voiriot G, Dury S, Parrot A, Mayaud C, Fartoukh M. Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia. Chest. 2011 Feb;139(2):387-394. doi: 10.1378/chest.09-3102. Epub 2010 Aug 19.</citation>
    <PMID>20724739</PMID>
  </reference>
  <reference>
    <citation>Messika J, Sztrymf B, Bertrand F, Billard-Pomares T, Barnaud G, Branger C, Dreyfuss D, Ricard JD. Risks of nonsteroidal antiinflammatory drugs in undiagnosed intensive care unit pneumococcal pneumonia: younger and more severely affected patients. J Crit Care. 2014 Oct;29(5):733-8. doi: 10.1016/j.jcrc.2014.05.021. Epub 2014 Jun 4. Review.</citation>
    <PMID>24997726</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>August 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>February 25, 2016</last_update_submitted>
  <last_update_submitted_qc>February 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Louis Mourier</investigator_affiliation>
    <investigator_full_name>Prof Jean-Damien RICARD</investigator_full_name>
    <investigator_title>Professor of Intensive Care Medicine, assistant head of ICU</investigator_title>
  </responsible_party>
  <keyword>Pneumonia, Bacterial [C01.252.620]</keyword>
  <keyword>Bronchopneumonia [C08.381.677.127]</keyword>
  <keyword>Pleuropneumonia [C08.730.610.473]</keyword>
  <keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

